JS

Jasper Therapeutics IncNASDAQ JSPR Stock Report

Last reporting period 31 Dec, 2023

Updated 18 Nov, 2024

Last price

Market cap $B

0.329

Micro

Exchange

XNAS - Nasdaq

JSPR Stock Analysis

JS

Uncovered

Jasper Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.329

Dividend yield

Shares outstanding

110.29 B

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 35 full-time employees. The company went IPO on 2019-11-20. The firm has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. The company is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The firm also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases. JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.

View Section: Eyestock Rating